Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05090358 · ClinicalTrials.gov registry record · Phase 2
Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer
A Phase 2 study of Breast Cancer and Metastatic Breast Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 9
- Study locations
NCT05090358 is a Phase 2 study of Breast Cancer and Metastatic Breast Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 15 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 9 study locations across 3 states.
The verdict
NCT05090358, a Phase 2 study of Breast Cancer and Metastatic Breast Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study to find out whether a very low carbohydrate diet (ketogenic diet), a low carbohydrate diet, or the study drug canagliflozin can prevent high blood sugar and may improve the effectiveness of cancer therapy in people who are receiving standard treatment with alpelisib and fulvestrant for their metastatic PIK3CA-mutant breast cancer.
Conditions Studied
Interventions
- DRUG Fulvestrant
- DRUG Alpelisib
- DIETARY_SUPPLEMENT Ketogenic Diet
- DIETARY_SUPPLEMENT Low Carbohydrate Diet
- DRUG Canagliflozin
Study Locations (9)
New York
- Memorial Sloan Kettering Suffolk - Commack (Limited protocol activity) - Commack
- Memorial Sloan Kettering Westchester (All protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Weill Cornell Medical College (Data Collection & Data Analysis) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Ohio
- Ohio State University (Data Collection & Data Analysis) - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-10-08 |
| Est. Completion | 2026-10-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05090358
The ClinicalTrials.gov registry entry for NCT05090358 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Fulvestrant is the first listed.
NCT05090358 reports 9 study locations spanning 3 distinct geographic areas - top geographies include New York, New Jersey, Ohio.
Frequently Asked Questions
What is clinical trial NCT05090358 about?
NCT05090358 is a clinical study titled "Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer". The purpose of this study to find out whether a very low carbohydrate diet (ketogenic diet), a low carbohydrate diet, or the study drug canagliflozin can prevent high blood sugar and may improve the effectiveness of cancer therapy in people who are receiving standard treatment with alpelisib and ful...
What is the current status of trial NCT05090358?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2021-10-08. Estimated completion is 2026-10-08.
What conditions does trial NCT05090358 study?
This clinical trial studies the following conditions: Breast Cancer, Metastatic Breast Cancer, Breast Cancer Stage IV.
What interventions are being tested in trial NCT05090358?
The interventions under investigation include: Fulvestrant (DRUG), Alpelisib (DRUG), Ketogenic Diet (DIETARY_SUPPLEMENT), Low Carbohydrate Diet (DIETARY_SUPPLEMENT), Canagliflozin (DRUG).
Who is sponsoring clinical trial NCT05090358?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05090358 being conducted?
This trial has 9 study locations across New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.